- Market analysts are of the opinion that the healthcare space is all set to witness growth, which might give potential to small companies to thrive upon.
- Rua Bioscience released its ASM presentation highlighting its four key pillars.
- Smaller healthcare companies can take the market by storm with their successful trials or launch of new products.
Healthcare is one of those few sectors which saw a boom amid the coronavirus pandemic, which otherwise caused a ruckus in every sphere of life worldwide.
On 19 October, benchmark, the S&P/NZX 50 Index, last traded at 13,065.92 points, up by 0.52%. Simultaneously, the S&P/NZX All Health Care last traded, up by 0.87% at 3,352.69 points.
With the economy returning to normal, market analysts are of the opinion that the healthcare space is all set to witness growth ahead. There is a lot of potential for small organisations to cash in on it.
On the given backdrop, let’s now take a peek at 5 NZX healthcare penny stocks.
Image source: © 2021 Kalkine Media New Zealand Ltd, data source- Refinitiv
TruScreen Group Limited (NZX:TRU)
Medical device entity TruScreen Group Limited published its Annual Meeting presentation on 7 September.
During the meeting, FY21 results and strategy for FY22 closing March 2022 were discussed, which outlined continuous product improvement and innovation, rapid expansion in China and constant development in other markets.
On 19 October, by the end of the trading session, TruScreen was flat at NZ$0.064.
Promisia Healthcare Limited (NZX:PHL)
Healthcare services provider Promisia Healthcare Limited runs elderly care facilities.
By the end of August, the Company informed the market about finalising its quarterly covenant reporting (correlated to a requirement towards EBITDA/interest cover to be no less than two times the interest price). The Company informed that Promisia was in violation of one of the two banking covenants during the June quarter.
By the close of the market session, on 19 October, Promisia was unchanged at NZ$0.001.
Rua Bioscience Limited (NZX:RUA)
NZ-domiciled therapeutic cannabis company Rua Bioscience Limited provided an ASM presentation to the market.
The Meeting included the Chairman’s commentary and reflection on FY21 that went by, which had proved transformational for the Company.
The meeting further discussed its strategy and four major pillars.
-Developing unique product and plant IP.
- Next, taking the IP and creating new products and markets.
- Then lay emphasis on optimising cultivation and processing.
- Lastly, development of their individuals.
On 19 October, Rua ended the day’s session decreasing by 2.44% at NZ$0.4.
Blis Technologies Limited (NZX:BLT)
Biotech entity developing advanced probiotics is based in Dunedin.
On 14 September, the Company provided an update on issued performance share rights without consideration to a few members of upper management. These performance share rights received directors’ nods on 10 September.
Blis closed the market session at NZ$0.061, decreasing by 1.61%, as on 19 October.
Penny stocks are usually volatile in nature, however, such stocks from the healthcare sector could surprise the market. Relatively, smaller healthcare companies can take the market by storm with their successful trials or launch of new products, followed by a surge in their prices.